Today, we announced positive Phase 3 results from our investigational TROP2-directed antibody-drug conjugate (ADC) in in the third-line or later treatment of certain patients with locally advanced or unresectable metastatic gastroesophageal adenocarcinoma, an area where there is significant unmet need: go.merck.com/~dkr
0:17